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Abstract
Background: The presence of cancer makes it difficult to predict the progress of pregnancy and
can be deleterious to the maternal-foetal relationship. Apoptosis may affect a range of placental
functions and result in the retardation of foetal growth. In this work, we investigated the placental
alterations produced by tumour growth and the effects on the expression of apoptotic factors in
placental tissue.
Methods: Adult female Wistar rats (90 days old, n = 54) were allocated to control (C), tumour-
bearing (W), or ascitic fluid-injected (A) groups and were killed on the 16th, 19th or 21st day of
pregnancy. Placental tissues were analysed using biochemical and histochemical assays.
Results: The placental protein content and glutathione-S-transferase activity were decreased in
groups W and A. Histochemical analysis showed an increase in the number of cells with cleaved
PARP, caspase 3 and cytochrome-c in groups W and A, indicating that the tumour growth clearly
damaged placental tissue and affected the levels of apoptotic factors. These results were confirmed
by western blotting.
Conclusion: Since trophoblastic cells are responsible for maintaining a normal placental function,
the uncontrolled death of these cells in response to tumour cell growth or substances derived from
ascitic fluid could have a negative impact on foetal development. Further knowledge of these events
may help to preserve the foetus and placenta during development.
Background
Cancer is the second most common cause of death during
the reproductive years [1] and complicates 0.02–0.1% of
all pregnancies [2]. However, the development of cancer
during pregnancy is difficult to predict [3]. Indeed, some
studies have suggested that pregnancy does not favour the
development of cancer and may protect the organism
against tumour growth [3,4]. Fast tumour growth during
pregnancy may result in damage to the foetus and lead to
foetal resorption and death [4-6]. Since foetal and tumour
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growth requires increased protein synthesis, the impor-
tance of amino acids in foetal life has been emphasised
[7].
The foetal nutrient supply depends on the mother's
reserves and food intake, as well as on the placental func-
tion. Placental growth increases during gestation, con-
comitant with or ahead of foetal growth [8], and a failure
in placental function can adversely affect foetal growth or
welfare [7]. The physiological changes that occur during
pregnancy can only be sustained if there is an appropriate
nutrient supply to ensure placental and foetal develop-
ment [7]. To guarantee the supply of nutrients essential to
foetal survival, the placenta continuously undergoes
changes in weight, structure, shape and function during
gestation [9].
The placenta-foetal metabolic relationships are complex,
dynamic processes that control many aspects of foetal
development. The exchange between maternal and foetal
blood occurs across the labyrinth layers of the placental
barrier. In rats, the placenta, which consists of three tro-
phoblast layers in the labyrinth zone, is the rate-limiting
permeability barrier to substrate exchange between the
maternal and foetal compartments [10].
Programmed cell death has been implicated in normal
and pathological processes in several human tissues and
diseases, including cancer [11,12]. Placental apoptosis
occurs during normal pregnancy [13,14], especially in tro-
phoblast cells, whereas excessive apoptosis of the syncyti-
otrophoblast and cytotrophoblast, including the
extravillar population, has been observed in pre-eclamp-
sia pregnancies [16-18]. Recently, a number of studies
have suggested that apoptosis plays a role in the normal
development, remodelling, and ageing of the placenta
[15,19,20], particularly in the second half of pregnancy
[15].
During apoptosis, the activation of caspases by nuclear,
metabolic or external stimuli occurs in a cascade fashion,
and results in nuclear engulfment and cell death [21,22].
Since apoptosis may affect a range of placental functions,
and since an increase in this process may be associated
with the retardation of foetal growth, we investigated the
influence of Walker 256 carcinosarcoma growth on the
organisation of the placenta in rats and on the presence of
apoptotic signals, such as cleaved PARP, cytochrome-c,
and caspase 3.
Methods
Animals
Adult female Wistar rats (90 days old, n = 54) were
obtained from the animal facilities of the State University
of Campinas (CEMIB-UNICAMP) and were housed with
adult males (four females per male) for 12 h [23]. Mating
was confirmed by analysing vaginal smears, with a posi-
tive result being considered as the first day of pregnancy.
The pregnant rats were allocated to one of three groups:
control (C), tumour-bearing (W), or injected with ascitic
fluid (A). All of the rats were housed in collective cages
under standard conditions (22 ± 2°C, 12 h light-dark
cycle) with free access to a semi-synthetic control diet
(AIN-93 G) [24].
Neoplastic implants and extraction of ascitic fluid
Walker 256 carcinosarcoma cells (2.5 × 105 in approxi-
mately 0.5 mL of 0.9%, w/v, NaCl), originally obtained
from the Arthur D'Little Hospital, USA, were injected sub-
cutaneously on the second day of pregnancy. Control rats
received 0.5 ml of 0.9% NaCl solution. Since we have pre-
viously shown that ascitic fluid from tumour-bearing rats
produces foetal death and resorption [4], we examined
the effect of this fluid on tumour growth. Ascitic fluid was
collected from the intraperitoneal cavity of Walker
tumour-bearing rats and was centrifuged (500 × g, 4°C, 10
min) to remove all neoplastic cells. From the 9th day of
pregnancy onwards, group A rats received daily injections
of 2 ml of ascitic fluid. The rats were killed 16, 19 or 21
days after mating, which corresponded to the 14th, 17th
and 19th day after tumour transplantation, or the 7th, 10th
and 12th day after ascitic fluid injection, respectively.
The general UKCCR (United Kingdom Co-ordinating
Committee on Cancer Research) guidelines for animal
welfare [25] were followed and the protocols were
approved by the institutional Committee for Ethics in
Animal Experimentation (CEEA/IB/UNICAMP, protocol
#217-3].
Histochemical analyses
The whole placental tissue from all rats were processed for
light microscopical immunohistochemistry after perfus-
ing the uterus, via the heart, with 10 mL of heparinized
saline followed by 20 mL of fixative solution containing
4% paraformaldehyde in phosphate-buffered saline
(PBS), pH 7.2. The fixed placentas were then removed,
dehydrated, and embedded in paraffin. Sections (at least
5 µm thick) were obtained for the immunohistochemical
detection of cleaved PARP, caspase 3 and cytosolic cyto-
chrome-c.
Placental cells were detected immunohistochemically
using anti-PARP [poly(ADP-ribose) polymerase] goat pol-
yclonal antibody (Santa Cruz Biotechnology, Santa Cruz,
CA; diluted 1:100) followed by incubation with bioti-
nylated rabbit anti-goat secondary antibody (1:500 dilu-
tion, Santa Cruz Biotechnology) for 1 h at room
temperature and further incubation with streptavidin
horseradish peroxidase solution (Vector Laboratories).BMC Cancer 2006, 6:168 http://www.biomedcentral.com/1471-2407/6/168
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The sections were reacted with diaminobenzidine (DAB,
Sigma) and H2O2 in PBS and stained with fast green. Cas-
pase-3 and cytochrome-c were detected using specific goat
polyclonal antibodies (Santa Cruz Biotechnology; diluted
1:250 and 1:100, respectively) and the biotinylated sec-
ondary antibody/streptavidin horseradish peroxidase
detection system described above. After incubation with
DAB and H2O2 in PBS, the sections were stained with Har-
ris' haematoxylin and lithium carbonate. For negative
controls, placental sections from each group were incu-
bated in PBS without the first antibody and then incu-
bated with the biotinylated anti-goat secondary antibody
followed by reaction with DAB, as described above.
The cells positive for cleaved PARP, caspase-3 and
cytosolic cytochrome-c were counted using Image Pro-
Plus software (v.3.01, Media Cybernetics, Silver Spring,
MD, USA) after capturing the image on a Leica micro-
scope (Leica DMLM, Weizlar, Germany) using a 100×
magnification for cleaved PARP images and a 40× magni-
fication for caspase-3 and cytochrome-c images. The
number of positive cells was determined by counting 20
fields (300 µm2 each) in one slide from each of at least six
dams per group.
Biochemical assays and Western blotting
The other portion of the uterus from all groups was used
to provide placental tissue for biochemical assays and
western blotting. Fragments of this tissue were stored at -
70°C until analysis. Placental samples (100 mg) were
homogenised in buffer (1:4, w/v, in 0.3 M Tris pH 8, 0.1
M NaCl, 10 mM EDTA, 0.2 M sucrose and 0.01% SDS)
and centrifuged at 10,000 × g for 15 min at 4°C. The total
protein content of the supernatants was determined color-
imetrically as described by Bradford [26]. The homoge-
nates were used to determine the glutathione-S-
transferase activity with the assay described by Habig et al.
[27]. Western blotting was used to assess changes in the
expression of cleaved PARP, caspase 3 and cytochrome-c
after SDS-PAGE of 20 µg of total protein in 12% polyacr-
ylamide gels. For western blots of cytochrome-c, the pla-
cental homogenates were subjected to three freeze-thaw
cycles to obtain a cytosolic fraction without mitochondria
prior to electrophoresis. The proteins were transferred to
0.45 µm nitrocellulose Hybond membranes (Amersham
Biosciences, Piscataway, NJ) and then incubated with pol-
yclonal antibodies against cleaved PARP (Santa Cruz Bio-
technology; diluted 1:500) and caspase 3 (Santa Cruz
Biotechnology; diluted 1:1000) or a monoclonal anti-
body against cytochrome-c (R&D, diluted 1:1000), fol-
lowed by detection with an anti-goat secondary
horseradish peroxidase (HRP)-labelled antibody (Dako,
Carpinteria, CA, USA, diluted 1:1500). Actin was used as
an internal control for protein loading and was detected
with an antibody to mouse actin. The nitrocellulose mem-
branes were developed using enhanced chemilumines-
cence (ECL reagent, Amersham Biosciences) and
densitometric analysis of the protein bands was done
using Gel-Pro Analyser software (Media Cybernetics,
1993–97, Silver Spring, MD, USA).
Statistical analysis
The results were expressed as the mean ± SEM. Inter- and
intragroup comparisons were done using one-way analy-
sis of variance (ANOVA) [28] followed by Dunn's multi-
ple comparison tests to determine the significance of the
differences among the groups. All statistical comparisons
were done with GraphPad Prism software (v 3.0, Graph-
The foetal and placental ratios of the control, tumour-bear- ing and ascitic fluid-injected groups Figure 1
The foetal and placental ratios of the control, tumour-bear-
ing and ascitic fluid-injected groups. The foetal weight and 
corresponding placental weight were plotted and the positive 
correlation between these parameters was analysed using 
GraphPad Prism software. There was a significant difference 
(*P < 0.05) between the tumour-bearing and ascitic fluid-
injected groups compared to the control rats. Groups: C – 
control rats, W – tumour-bearing rats and A – rats injected 
with ascitic fluid. The rats in each group were sacrificed on 
the 16th, 19th and 21st day of pregnancy.
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Pad Inc., San Diego, CA, USA), with a value of P < 0.05
indicating significance.
Results
Influence of Walker 256 tumour and ascitic fluid on foetal 
and placental parameters
The foetal and placental ratio was altered by tumour
growth and the injection of ascitic fluid. Figure 1 shows
the reduction in the foetal and placental ratio in groups W
and A, with different correlations for each curve (P <
0.05).
The placental protein levels of the control groups were
similar, regardless of the gestational stage (C16 = 2.23 ±
0.11, C19 = 2.22 ± 0.12 and C21 = 2.19 ± 0.10 µg/µL; n =
8 each). In the tumour groups, the protein content was
significantly lower (P < 0.05) than in the corresponding
control only for W21 (W16 = 2.12 ± 0.16, W19 = 2.15 ±
0.06 and W21 = 1.64 ± 0.18 µg/µL; n = 8 each). A signifi-
cant decrease in the protein content (~27%; P < 0.05) was
seen in all groups injected with ascitic fluid (A16 = 1.38 ±
0.09, A19 = 1.59 ± 0.09 and A21 = 1.58 ± 0.08 µg/µL; n =
8 each).
Glutathione-S-transferase (GST) activity is associated with
the cell cycle and is responsible for the conjugation and
detoxification of intermediates produced by oxidative
stress in rat placenta [29]. There was a non-linear decrease
in GST activity during pregnancy in the control groups
(C16 = 23.94 ± 1.83, C19 = 31.71 ± 4.28*, and C21 =
14.89 ± 1.31* nmol/µg protein, n = 8; *P < 0.05 com-
pared to the C16 group), since the high GST activity seen
on the 19th day may be related to the maximal placental
function at this time interval, as previously reported [30].
Tumour-bearing rats showed a significant decrease in GST
activity on days 19 and 21 when compared to the corre-
sponding control groups (W16 = 21.23 ± 2.15, W19 =
20.47 ± 1.94 and W21 = 9.23 ± 1.84 nmol/µg protein; n =
8; P < 0.05). These results indicated an attenuation of the
cellular protective mechanisms during tumour growth
that could possibly compromise placental function and
affect foetal development, as previously demonstrated
[4,30].
Similar data were obtained in the ascitic fluid group, in
which GST activity was reduced on the 19th and 21st days
(A16 = 17.73 ± 2.65, A19 = 13.94 ± 1.50 and A21 = 11.15
± 1.17 nmol/µg protein, n = 8; P < 0.05) compared to the
control group. These data suggest that the presence of
ascitic fluid decreases the protective action of anti-oxida-
tive enzymes such as GST.
Influence of Walker 256 tumour and ascitic fluid on the 
immunohistochemical detection of placental cleaved 
PARP, cytochrome-c and caspase-3
The placental histological layer investigated here was the
junctional zone, which contains cytotrophoblastic cells,
trophoblastic giant cells and vesicular glycogen cells [31]
(see Figure 2A for a placental section from a control rat on
the 20th day of pregnancy). The labyrinth zone is not
shown since the alterations in this zone were the same as
those in the junctional zone
PARP is a nuclear protein implicated in DNA repair and is
the earliest protein cleaved to a specific 89 kDa fragment
(cleaved PARP) during apoptosis [32]. Immunohisto-
Table 1: Placental immunohistochemical analysis of cleaved PARP, caspase-3 and cytosolic cytochrome-c (number of positive cells 
counted) and the ratios of cleaved PARP, caspase-3 and cytosolic cytochrome-c positive cells in the spongy trophoblast layer of 
tumour-bearing rats or rats injected with ascitic fluid compared to control rats at different stages of pregnancy (16th, 19th and 21st 
days). Polyclonal antibodies against PARP, caspase-3 and cytochrome-c (all from Santa Cruz Biotechnology; anti PARP and anti-
cytochrome-c diluted 1:100; anti-caspase diluted 1:250) were detected with a secondary biotinylated anti-goat antibody (diluted 1:500) 
and reacted with DAB in the presence of H2O2. The cells were counted using Image ProPlus software.
Number of positive cells counted Ratio between treated and control groups
Cleaved 
PARP
Caspase-3 Cytosolic 
cytochrome-c
Cleaved 
PARP
Caspase-3 Cytosolic 
cytochrome-c
C16 43.1 ± 7.1a 3.7 ± 0.4a 3.4 ± 0.3a
W16 136.7 ± 12.2b 16.0 ± 1.4c 4.7 ± 0.3a W16/C16 2.89 ± 0.30a 3.02 ± 0.37a 1.52 ± 0.11a
A16 71.7 ± 9.2c 7.9 ± 0.4c 6.7 ± 0.4c A16/C16 1.41 ± 0.13b 2.90 ± 0.35a 2.54 ± 0.25b
C19 48.0 ± 5.9a 1.3 ± 0.2b 4.9 ± 0.3a
W19 149.2 ± 20.9b 9.3 ± 0.7c 13.3 ± 0.7b W19/C19 3.40 ± 0.23a 7.56 ± 0.74b 3.03 ± 0.20b
A19 115.9 ± 9.5b 4.6 ± 0.2a 15.4 ± 0.4d A19/C19 3.00 ± 0.30a 3.84 ± 0.34a 3.35 ± 0.21b
C21 54.8 ± 7.6a 2.5 ± 0.3a 4.8 ± 0.3a
W21 148.0 ± 16.9b 7.3 ± 0.7c 12.7 ± 0.6b W21/C21 2.99 ± 0.54a 2.50 ± 0.70a 3.00 ± 0.22b
A21 73.4 ± 11.7c 7.2 ± 0.4c 10.2 ± 0.6b A21/C21 1.67 ± 0.36b 2.43 ± 0.50a 2.78 ± 0.29b
Groups: control (C), tumour-bearing (W) and ascitic fluid-injected (A) rats. Twenty areas (300 µm2 each) were examined in one tissue section each 
from at least six rats per group. The cells were counted using Image ProPlus software. The results are expressed asthe mean ± SEM. Different 
superscript letters indicate significant differences within each column (P < 0.05).BMC Cancer 2006, 6:168 http://www.biomedcentral.com/1471-2407/6/168
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chemical analysis for cleaved PARP revealed few stained
nuclei in sections from the control groups (Figure 2A–C).
However, in the nuclei that were positive, the staining was
strong, especially in cytotrophoblastic and trophoblastic
giant cells. Compared to the corresponding controls, there
was a significant increase in the number of nuclei positive
for cleaved PARP in tumour-bearing rats (W16, W19 and
W21), regardless of the gestational stage (Figure 2D,E and
2F, respectively). The ratio of positive cells (those with
stained nuclei) in the W and C groups showed that the
level of cleaved PARP increased by about three-fold,
regardless of the gestational stage (Table 1). Similar results
were obtained in all of the ascitic fluid groups, with strong
nuclear staining, particularly in cytotrophoblastic and tro-
phoblastic giant cells (Figure 2G,H, and 2I, which corre-
spond to A16, A19 and A21, respectively). The ratio of
positive cells in the ascitic fluid and control groups indi-
cated an ~1.5-fold increase in the former group compared
to the controls, but this increase was not as high as in the
W group, except on the 19th day of pregnancy (Table 1).
Cytochrome-c showed a similar distribution in the cytosol
of placental cells during different stages of pregnancy in
the control groups (the number of positive cells was sim-
ilar in C16, C19 and C21; Figure 3A,B, and 3C, respec-
tively, and Table 1). In tumour-bearing rats, there was
enhanced staining for cytosolic cytochrome-c, particularly
in cytotrophoblastic and trophoblastic giant cells (Figure
3D,E, and 3F, corresponding to W16, W19 and W21,
respectively). The cytosolic staining for cytochrome-c was
disperse and enhanced in the ascitic fluid groups at all
stages of pregnancy (Figure 3G,H, and 3I, corresponding
to A16, A19 and A21, respectively).
There was a slight increase in cytosolic staining for cas-
pase-3 expression in the placenta of control dams at C16,
the first stage of pregnancy, compared to the other days
(C19 and C21) (Table 1 and Figure 4A,B and 4C, which
correspond to C16, C19 and C21, respectively). Com-
pared to control rats, the tumour-bearing rats and rats
injected with ascitic fluid showed a significant increase in
caspase-3 staining in the cytosol of cytotrophoblastic and
trophoblastic giant cells, with positive cells in all stages of
pregnancy (P < 0.05) (Figure 4D,E and 4F for group W and
Figure 4G,H and 4I for group A) (Table 1). The ratio of
positive cells in groups W and A compared to the corre-
sponding controls indicated a three-fold increase in cas-
pase-3 expression at all gestational stages, except for group
W19, for which the increase was approximately seven-fold
(Table 1).
The expression of cleaved PARP, cytochrome-c and 
caspase 3 in rat placenta
Western blotting showed that the expression of cleaved
PARP (89 kDa band) in placental tissue was significantly
enhanced on the 21st day in group W and on the 16th and
21st days in group A; the increase on the 21st day was
around two- and three-fold higher in groups W and A,
respectively (Figure 5A, Table 1). There is a positive corre-
lation between gestational stage and the levels of the 89-
kDa fragment and placental apoptosis during normal
pregnancy [33]. Our findings indicate that there was acti-
vation on apoptosis process due to the tumour growth or
the presence of ascitic fluid. The expression of cyto-
Immunohistochemical detection of cleaved PARP in placental  tissue at different stages of pregnancy (days 16, 19 and 21) Figure 2
Immunohistochemical detection of cleaved PARP in placental 
tissue at different stages of pregnancy (days 16, 19 and 21). 
Cleaved PARP was detected using a polyclonal antibody 
(Santa Cruz; diluted 1:100) followed by incubation with a 
biotinylated anti-goat antibody (1:500) and reaction with 
DAB in the presence of H2O2. The tissue sections are from 
the placental junctional zone, which contains cytotrophoblas-
tic cells (c) and trophoblastic giant cells (gc). The arrows indi-
cate nuclei with immunostaining for cleaved PARP. Groups: 
C – control rats, corresponding to images A, B and C on the 
16th, 19th and 21st day, respectively, W – tumour-bearing rats, 
corresponding to images D, E and F on the 16th, 19th and 21st 
day, respectively, and A – rats injected with ascitic fluid, cor-
responding to images G, H and I on the 16th, 19th and 21st 
day, respectively. Image J is a negative control. Magnification 
– 100×. Horizontal bar = 100 µm.
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chrome-c in the control groups was similar, regardless of
the stage of pregnancy (Figure 5C). The principal death-
signalling pathway involves mitochondria that, in
response to various stimuli, can release cytochrome-c into
the cytosol where this enzyme triggers apoptotic effectors
such as caspase activation [34]. An increase in the expres-
sion of placental cytochrome-c in groups W and A, espe-
cially on the 16th  and 19th  days, with an additional
increase on the 21st day in rats given ascitic fluid (Figure
5C), suggested the occurrence of tissue damage caused by
the tumour or by products synthesized by the tumour
and/or host cells present in ascitic fluid. Western blotting
revealed a tendency towards increased caspase-3 expres-
sion during pregnancy in the tumour and ascitic fluid
groups, especially on the 19th and 21st days (Figure 5B).
Discussion
The nutritional demand of tumour cells is extremely high
[35] and may produce metabolic alterations that can com-
promise the availability of amino acids and other nutri-
Immunohistochemical detection of caspase-3 in placental tis- sue in different stages of pregnancy (days 16, 19 and 21) Figure 4
Immunohistochemical detection of caspase-3 in placental tis-
sue in different stages of pregnancy (days 16, 19 and 21). Cas-
pase 3 was detected using a polyclonal antibody (Santa Cruz 
Biotechnology, diluted 1:100) followed by incubation with 
biotinylated anti-goat antibody (1:500) and reaction with 
DAB in the presence of H2O2. The arrows indicate the cyto-
plasmic immunostaining of caspase-3 in trophoblastic cells. 
The tissue section contains cytotrophoblastic cells (c), tro-
phoblastic giant cells (gc) and vesicular glycogen cells (v). 
Groups: C – control rats, corresponding to images A, B and 
C on the 16th, 19th and 21st day, respectively, W – tumour-
bearing rats, corresponding to images D, E and F on the 16th, 
19th and 21st day, respectively, and A – rats injected with 
ascitic fluid, corresponding to images G, H and I on the 16th, 
19th and 21st day, respectively. Image J is a negative control. 
Magnification – 40×. Horizontal bar = 10 µm.
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Immunohistochemical detection of cytosolic cytochrome-c in  placental tissue in different stages of pregnancy (days 16, 19  and 21) Figure 3
Immunohistochemical detection of cytosolic cytochrome-c in 
placental tissue in different stages of pregnancy (days 16, 19 
and 21). Cytochrome-c was detected using a polyclonal anti-
body (Santa Cruz Biotechnology, diluted 1:100) followed by 
incubation with a biotinylated anti-goat antibody (1:500) and 
reaction with DAB in the presence of H2O2. The arrows 
indicate the cytoplasmic immunostaining of cytochrome-c in 
trophoblastic cells. The tissue section contains cytotrophob-
lastic cells (c), trophoblastic giant cells (gc) and vesicular gly-
cogen cells (v). Groups: C – control rats, corresponding to 
images A, B and C on the 16th, 19th and 21st day, respectively, 
W – tumour-bearing rats, corresponding to images D, E and 
F on the 16th, 19th and 21st day, respectively, and A – rats 
injected with ascitic fluid, corresponding to images G, H and I 
on the 16th, 19th and 21st day, respectively. Image J is a nega-
tive control. Magnification – 40×. Horizontal bar = 10 µm.
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Densitometric analysis of western blots (WB) of cleaved PARP (89 kDa; A), caspase 3 (32 kDa; B) and cytosolic cytochrome-c  (34 kDa; C) and WB images of cleaved PARP, caspase-3 and cytosolic cytochrome-c in the spongy trophoblast of control,  tumour-bearing and ascitic fluid-injected rats on the 16th, 19th and 21st day of pregnancy Figure 5
Densitometric analysis of western blots (WB) of cleaved PARP (89 kDa; A), caspase 3 (32 kDa; B) and cytosolic cytochrome-c 
(34 kDa; C) and WB images of cleaved PARP, caspase-3 and cytosolic cytochrome-c in the spongy trophoblast of control, 
tumour-bearing and ascitic fluid-injected rats on the 16th, 19th and 21st day of pregnancy. Cleaved PARP (antibody dilution 
1:500), caspase-3 and cytochrome-c (antibody dilution 1:1000) were detected with polyclonal antibodies from Santa Cruz Bio-
technology and enhanced chemiluminescence. For details see Materials and Methods. The band intensities (expressed in arbi-
trary densitometric units) were analysed using Gel-Pro Analyser software. Actin was used as an internal control for protein 
loading and was detected with an antibody to mouse actin. The WB images are representative of eight separate blots. Groups: 
C – control, W – tumour-bearing, and A – ascitic fluid-injected rats. The results are expressed as the mean ± SEM of at least 
six rats per group. Different superscript letters indicate significant differences (P < 0.05) within each column.
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ents to foetal tissues [36]. Ascitic fluid contains many
factors capable of causing oedema and haemorrhage in
the placenta of pregnant rats [37] and of decreasing the
placental glycogen stores in tumour-bearing rats [30].
An optimal maternal-foetal exchange is necessary for a
successful pregnancy. Complications associated with
pregnancy, including limited intrauterine growth and pre-
eclampsia, have been related to poor trophoblast invasion
and/or placental insufficiency that may result in placental
ischemia and oxidative stress [38]. However, the mecha-
nisms by which placental oxidative stress triggers the char-
acteristic placental endothelial dysfunction responsible
for the development of pre-eclampsia are not well under-
stood [38]. Placental anti-oxidative mechanisms play an
important role during pregnancy, as shown by the ele-
vated activities of GSH, GST isoenzymes and GST and
GPX [38]. Cervello et al. [29] studied pregnant rats treated
with benzo(a)pyrene and reported an increase in the anti-
oxidative capacity, seen as enhanced GST activity in the
placental tissue of these rats compared to non-treated ani-
mals. However, these authors concluded that the increase
in GST activity was insufficient to protect the foetus and
that benzo(a)pyrene significantly increased the number
of resorptions and reduced the foetal weight [29].
As shown here, there was a marked reduction in the GST
activity of placental tissue in groups W and A. Assuming
that tumour growth during pregnancy induces foetal
resorption and death [4] and jeopardises the placental tis-
sue by causing placental oedema [37] and a reduction in
the level of placental glycogen [30], the changes in placen-
tal GST activity seen here could have an antioxidant func-
tion and may occur in parallel with programmed cell
death. In late gestation in humans, there is increased oxi-
dative stress in pregnancies complicated by diabetes,
intrauterine growth retardation (IUGR) and preeclamp-
sia, as well as increased trophoblast apoptosis and depor-
tation, and altered placental vascular reactivity [39].
Tumour growth clearly damaged the placental tissue by
altering the foetal/placental ratio and the levels of apop-
totic signalling molecules such as cleaved PARP, cyto-
chrome-c and caspase 3. Tumours can damage foetuses
(high foetal resorption, foetal death or a decrease in foetal
growth) through competition for nutrients and by harm-
ing the foetus and placenta indirectly through substances
synthesized by the tumour and/or host cells present in
ascitic fluid [4]. Apoptosis occurs during normal develop-
ment in different organs and tissues and is a normal phe-
nomenon in trophoblast turnover, with no inflammatory
response in the mother. Apoptosis is important for an
appropriate balance in cell turnover, with the early, revers-
ible stages of the apoptotic cascade being involved in the
differentiation and fusion of the cytotrophoblast in ani-
mal models of pregnancy [39-42].
Normal placental development depends upon the differ-
entiation and invasion of the trophoblast, the main cellu-
lar component of the placenta. Apoptosis in the
trophoblast increases in normal placentas as gestation
proceeds, with a higher incidence in pregnancies compli-
cated by preeclampsia or IUGR [41]. Apoptosis is trig-
gered by different cell-type-specific signals that involve
mitochondrial and receptor-mediated pathways and
results in activation of the caspase cascade. At least two
major mechanisms by which a caspase cascade may be ini-
tiated have been suggested: one involves death receptors
that activate initiator caspases [43] and the other involves
cytochrome-c release [44]. There is evidence for the occur-
rence of one of the apoptotic pathways induced by cyto-
chrome-c in the placenta of tumour-bearing rats and in
rats injected with ascitic fluid. Further studies need to
address other apoptotic pathways involved during
tumour growth in placenta. Hung et al. [45] reported that
hypoxia-reoxygenation in vitro stimulated apoptosis in
human placental tissue, and that there was a significant
increase in cytochrome-c release from mitochondria asso-
ciated with intense immunolabelling for active caspase 3
in the syncytiotrophoblast and foetal endothelial cells.
There was also increased labelling of syncytiotrophoblas-
tic nuclei for cleaved PARP, and higher cytosolic concen-
trations of cleaved PARP in placental tissue under hypoxia
[45].
In agreement with these findings, we observed increased
caspase 3 expression in groups W and A that may have
been initiated by the release of cytochrome-c into the
cytosol [46]. Indeed, the injection of ascitic fluid increases
caspase 3 activity [47], which then cleaves PARP, one of
many caspase substrates, thereby preventing this enzyme
from repairing damaged DNA [48]; this lack of repair can
lead to apoptosis. Western blotting showed an increase in
cleaved PARP and caspase 3 expression in groups W and A
that was also associated with a progressive enhancement
of the cytochrome-c levels in both groups. These results
may indicate that placental layers, especially the trophob-
last, may experience greater apoptosis mediated by cyto-
chrome-c release and caspases, including caspase-3, which
is activated by several death receptors [43]. Such activa-
tion could be related to the decrease in GST activity seen
in groups W and A. This would allow the formation of
reactive oxygen species [49], which could in turn activate
other apoptotic pathways [50,51]. Various studies have
reported increased apoptosis following B19 infection of
villous trophoblastic cells [52], an elevation in caspase 3
activity and cytochrome-c release in chorionic villi after
exposure to ultrasound [53], and higher apoptotic rates inBMC Cancer 2006, 6:168 http://www.biomedcentral.com/1471-2407/6/168
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placentas from pregnancies complicated with intrauterine
growth restriction [54].
Conclusion
Since trophoblastic cells are responsible for maintaining a
normal placental function, the association to tumour
growth and/or substances produced by tumour cells, such
as cytokines and factors present in ascitic fluid, could be
involved in the uncontrolled death of trophoblastic cells
that have a negative impact on foetal development. Fur-
ther work are underway in our laboratory to improve our
understanding of the events that occur at the maternal-
foetal interface in the presence of tumours, especially with
regard to the role of cytokines present in ascitic fluid. Such
knowledge may help to improve the welfare of the foetus
and placenta during tumour development.
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